Albert Seals, MD
Cardiovascular Disease · Jacksonville, FLNPI 1568466159
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,310 of the $92,217 with a category attached, or 86.0%. Johnson & Johnson accounts for 75.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $27,285 and has fallen 94.9% since, to $1,393 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $518.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$70K
- Esperion Therapeutics, Inc.$16K
- Amgen$2K
- Chiesi USA, Inc.$757
- Abbott$687
- Novartis$407
- plus $3K from 23 others
Across 1 payment — averaging $13,744 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$14K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$79,31086%
- Travel & lodging$4,1204%
- Food & beverage$8,4829%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 79 | $69,727 |
| Esperion Therapeutics, Inc. | 17 | $16,086 |
| Amgen | 23 | $1,777 |
| Chiesi USA, Inc. | 3 | $757 |
| Abbott | 7 | $687 |
| Novartis | 5 | $407 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $384 |
| Novo Nordisk | 2 | $244 |
| Cleerly, Inc. | 1 | $220 |
| ZOLL Circulation Inc | 2 | $202 |
| Janssen Scientific Affairs, LLC | 8 | $156 |
| Boehringer Ingelheim | 2 | $141 |
| Sanofi-aventis U.S. LLC | 2 | $135 |
| Philips North America LLC | 2 | $134 |
| AstraZeneca | 2 | $132 |
| Abiomed | 1 | $132 |
| Boston Scientific | 1 | $125 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $123 |
| Edwards Lifesciences | 2 | $121 |
| Pfizer | 3 | $121 |
| Siemens Medical Solutions USA, Inc. | 1 | $118 |
| Sanofi | 1 | $110 |
| Shockwave Medical, Inc | 1 | $56 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Merck | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Gilead | 1 | $16 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$68,403
- NEXLIZET$15,819
- NEXLETOL$15,819
- Repatha$1,036
- RETAVASE$757
- Wegovy$244
- LEQVIO$232
- TRICLIP$222
- Cleerly Ischemia$220
- Cleerly Labs$220
- MitraClip System$147
- Mitra Clip system$141
- ENTRESTO$133
- Impella$132
- WATCHMAN Access System$125
- ARCALYST$123
- JARDIANCE$122
- Artis icono floor$118
- PRALUENT$118
- FARXIGA$116
How this compares
$92,217 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 140 | $142,507 |
| EliquisApixaban | 167 | $142,177 |
| XareltoRivaroxaban | 131 | $130,167 |
| Repatha SureclickEvolocumab | 49 | $55,834 |
| NexlizetBempedoic Acid/Ezetimibe | 46 | $25,528 |
| Rosuvastatin Calcium | 504 | $7,155 |
| Ezetimibe | 205 | $5,423 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $4,195 |
| Metoprolol Succinate | 211 | $2,962 |
| Atorvastatin Calcium | 341 | $2,735 |
| Ranolazine ErRanolazine | 14 | $2,291 |
| Losartan Potassium | 210 | $1,852 |
| Prasugrel Hcl | 24 | $1,825 |
| Amiodarone Hcl | 119 | $1,584 |
| Metoprolol Tartrate | 273 | $1,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $407 | $142,507140 claims |
| PfizerEliquis | $121 | $142,177167 claims |
| Johnson & JohnsonXarelto | $69,727 | $130,167131 claims |
| Esperion Therapeutics, Inc.Nexlizet | $16,086 | $25,52846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.